ABSTRACT Background: Although cross-sectional studies have shown that plasma S-adenosylhomocysteine (SAH), the metabolic precursor of homocysteine, is associated with cardiovascular disease, the prospective relation between plasma SAH and cardiovascular disease risk is unknown. Objective: The aim of this study was to prospectively evaluate the association between plasma SAH and cardiovascular disease risk in coronary angiography patients. Design: Baseline plasma SAH and homocysteine concentrations were measured in 1003 patients aged between 21 and 87 y who underwent coronary angiography. Cox proportional hazards models were used to analyze the association between SAH and homocysteine and the risk of cardiovascular events, including fatal cardiovascular diseases, nonfatal myocardial infarction, and stroke. Results: During the median follow-up period of 3.0 y, 93 participants developed cardiovascular events (32.7/1000 person-years). The age-and sex-adjusted hazard ratio of cardiovascular events was 3.38 (95% CI: 2.12, 5.39) for each 1-SD increase in the natural log-transformed SAH concentration. The age-and sex-adjusted hazard ratios of cardiovascular events across quartiles of SAH concentrations were 1.0, 2.25, 2.72, and 3.40 (P-trend = 0.007). Further adjustment for other cardiovascular disease risk factors and plasma homocysteine affected the results only slightly. This positive association between SAH and cardiovascular disease risk did not change when participants were stratified by age group, sex, and other baseline covariates. The results among a subset of participants with significant coronary stenosis were similar. Conclusion: Higher concentrations of plasma SAH are independently associated with an increased risk of cardiovascular events among patients undergoing coronary angiography. This trial was registered at www.chictr.org as ChiCTR-RNRC-08000270. Am J Clin Nutr 2013;98:1162-9.
INTRODUCTION
Over the past few decades, abundant epidemiologic studies have established that hyperhomocysteinemia is an independent risk factor for cardiovascular disease (CVD) 4 (1). In addition, in animal models, elevated plasma total homocysteine (tHcy) is considered to be a causal factor for atherosclerosis (2) . However, most recent large-scale clinical trials have shown that folic acid and B vitamin therapy aimed at reducing tHcy concentrations does not reduce the risk of CVD (3) . Nevertheless, vitamin therapy for lowering tHcy concentrations reduced the risk of stroke in patients without renal failure (4) .
S-adenosylhomocysteine (SAH) is produced as a product of methylation reactions involving S-adenosylmethionine (SAM) as the methyl donor, as shown in Figure 1 . SAH is the precursor of homocysteine that is produced in the body and is reversibly hydrolyzed to homocysteine and adenosine by SAH hydrolase. Homocysteine can be remethylated by methionine synthase with 5-methyltetrahydrofolate as the methyl donor or the vitamin B-12-dependent enzyme system or it can accept a methyl group from betaine to regenerate methionine. Alternatively, homocysteine can be degraded into cystathionine by the vitamin B-6-dependent cystathionine-b-synthase (5-7). Several previously reported cross-sectional studies have shown that plasma SAH increases as tHcy increases and that it is a more sensitive indicator of CVD (8) (9) (10) . However, the prospective relation between plasma SAH and CVD risk is unknown. As such, we investigated the association between baseline plasma SAH concentrations and the risk of cardiovascular events in a large prospective cohort of patients who underwent coronary angiography.
SUBJECTS AND METHODS

Study population
The Guangzhou Cardiovascular Disease Cohort Study is an ongoing, multicenter, prospective cohort study of the risk factors for CVD. As part of the Guangzhou Cardiovascular Disease Cohort Study, the current analysis included 1079 consecutive inpatients and outpatients aged between 21 and 87 y who underwent coronary angiography and were enrolled from Guangzhou Military General Hospital, Sun Yat-Sen Memorial Hospital, and Zhujiang Hospital between December 2008 and September 2009 in Guangzhou, China. The inclusion criteria were stable clinical conditions, except for acute coronary syndromes, and the availability of a coronary angiogram. The indications for angiography in individuals with clinically stable conditions were chest pain and /or noninvasive test results consistent with myocardial ischemia. The exclusion criteria were critical illness or hemodynamic instability other than acute coronary syndromes, surgery, or trauma within the previous month, known cancer, hepatic failure or hepatitis, or the use of drugs, such as anticancer agents, which would affect plasma tHcy concentrations. Of the 1079 patients, 76 patients with insufficient stored blood specimens for baseline SAH measurement were excluded, which resulted in a final study cohort consisting of 1003 patients. Of these, 320 patients had symptoms of unstable angina and 683 had symptoms of stable angina ( Figure 2) . The study was approved by the Ethical Committee of Sun Yat-sen University, and signed informed consent was obtained from all of the participants. All of the protocols adhered to institutional guidelines and to the Helsinki Declaration.
Coronary angiography was performed in all of the patients with the standard Judkins technique through the femoral artery or brachial artery. The angiograms were interpreted by 2 or more independent cardiologists who were unaware of the patients' risk-factor profiles. All of the evaluations were performed based on the American Heart Association protocol (11) . Significant coronary artery disease (CAD) was defined by .50% stenosis in at least 1 major coronary artery, including the left main coronary artery or the left anterior descending coronary artery, the right coronary, or the circumflex coronary artery. The extent of CAD was scored as 0 (minimal or no disease), 1 (single-vessel disease), 2 (2-vessel disease), or 3 (3-vessel disease) according to the number of main vessels with .50% stenosis.
Baseline measurements
Information on age, current smoking status, alcohol consumption, leisure-time physical activity, education, a family history of CAD (defined as an immediate relative receiving a diagnosis of having CAD before the age of 60 y), a history of hypertension and diabetes, and the use of medications was collected by using a questionnaire during a clinical visit. Habitual dietary intake was assessed by using a validated food-frequency questionnaire (12) , and nutrient consumption was calculated based on the 2002 Chinese Food Composition Tables (13) . Before the data were entered into a database, the questionnaires were checked by a trained interviewer for missing data and completeness. At the same clinical visit, body weight, height, waist and hip circumferences, and blood pressure were measured by using standard techniques in triplicate, and the averaged values were used for the analysis. BMI was calculated by dividing the patients' weight (in kg) by their height (in m) squared. Hypertension was defined as a systolic blood pressure .140 mm Hg and/or a diastolic blood pressure .90 mm Hg or the use of antihypertensive medication. Diabetes was considered to be present if there was a history of diabetes, if there was a fasting blood glucose concentration .126 mg/dL, or if the patient was taking antidiabetic medication.
Biochemical measurements
After the patients had fasted overnight, samples of venous blood were collected in tubes containing EDTA before coronary angiography. The plasma was separated from the blood cells by immediate centrifugation. For the SAH and SAM measurements, the plasma samples were divided into 500-mL aliquots, immediately acidified with 50 mL of 1 mol/L acetic acid to a final acetic acid concentration of 0.091 mol/L, mixed thoroughly, and stored at 2808C until analyzed (14) . The plasma tHcy and cysteine concentrations were measured simultaneously by HPLC with fluorescence detection (15) . Plasma SAH and SAM were measured by stable-isotope dilution HPLC with online electrospray ionization triple quadruple tandem mass spectrometry (Agilent Technologies Inc) (14, 16 The serum folate concentration was measured in a 96-well plate microbiological assay with Lactobacillus casei as the assay organism (17) . Serum vitamin B-12 was measured by using Immulite Chemiluminescent kits according to the manufacturer's instruction and performed with ARCHITECT 2000 analyzer (Abbott Laboratories Inc). Serum lipid concentrations (including total cholesterol, triglycerides, and HDL cholesterol), creatinine, and fasting blood glucose were measured by using routine methods. LDL cholesterol was calculated by using the Friedewald formula.
Prospective follow-up
The outcomes of the current study were defined as cardiovascular events during follow-up, which included death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke. We first contacted each participant by telephone twice per year to follow the doctor-diagnosed disease status and death status of the individual. We then retrieved the medical records, corresponding to the discharge diagnosis and exact discharge date, which were located at different hospitals. Furthermore, we questioned the treating doctors regarding the diagnosis of patients. Last, the outcome status of every patient was adjudicated by 2 doctors (YZ and XL). If the judgment was inconsistent, another doctor was required to make a decision (JQ). We assessed death status in all of the study participants, but only assessed nonfatal myocardial infarction and stroke in the participants who had not previously had such an event. The follow-up of all of the participants continued until the date of death and the onset of nonfatal myocardial infarction, nonfatal stroke from the hospital discharge register, or 1 June 2012. The ninth and tenth revisions of the International Classification of Disease were used to identify nonfatal myocardial infarction (410-411 and I21-I22, I24), nonfatal stroke (430-436 and I60-I66), and death from CVD (401-448 and I21-I68). Myocardial infarction was confirmed if the symptoms met World Health Organization criteria and if the event was associated with either diagnostic electrocardiogram changes or elevated cardiac or enzymatic biomarkers. Stroke was diagnosed as a new neurologic deficit of sudden onset that persisted for .24 h or until death within 24 h. Hemorrhagic and ischemic strokes were distinguished by computed tomographic scans, clinical information, and MRI. Death from cardiovascular causes was confirmed by examination of the autopsy reports, death certificates, and medical records.
Statistical analysis
Differences in the means, medians, or proportions of CVD risk factors between subjects with and without incident cardiovascular events were assessed with t tests, Wilcoxon's rank-sum tests, or chi-square tests. The cumulative event plot, according to the quartile of plasma SAH, was estimated by using the KaplanMeier method and compared by using the log-rank test. Because the distribution of plasma SAH concentrations in the population was positively skewed, natural log-transformed SAH concentrations were treated as a continuous variable in the analyses. Cox proportional hazards regression models were used to analyze the association of SAH and tHcy with the risk of incidence of cardiovascular events. The quartiles of plasma SAH and tHcy concentrations were included as dummy variables in the models, and the significance of the trend across quartiles of plasma SAH and tHcy was tested in the same models by giving an ordinal numeric value for each dummy variable. The proportional hazards assumption in the Cox model was assessed by using graphic methods and with models including time-by-covariate interactions (18) . All of the proportionality assumptions were appropriate. The analyses were first performed after adjustment for age and sex. Then, they were further adjusted for smoking, alcohol consumption, physical activity, education, dietary energy, fiber, BMI, systolic blood pressure, fasting glucose, LDL and HDL cholesterol, use of cholesterol-lowering agents, use of antidiabetic drugs, use of antihypertensive drugs, use of aspirin, family history of CAD, extent of CAD, and other metabolic markers. Because the interaction between sex and the SAH concentration on CVD risk was not statistically significant, the data for men and women were combined in the analyses to maximize the statistical power.
We also performed stratified analyses by baseline covariates and tests for interaction between SAH and age, sex, and other traditional CVD risk factors with CVD risk. To evaluate the combined effect of SAH and tHcy on CVD risk, we used 2 categories of tHcy and SAH as determined by the medians. To exclude the influence from the patients with no significant coronary stenosis, additional sensitivity analyses were carried out in the 861 patients with significant CAD. The estimated HRs (and 95% CIs) are presented. The differences were considered to be statistically significant if P , 0.05. All of the computations were carried out with SPSS 13.0 software (SPSS Inc).
RESULTS
Baseline characteristics
During the median follow-up period of 3.0 y, 18 patients were lost to follow-up and 93 participants developed cardiovascular events. Specifically, there were 35 deaths from cardiovascular causes, 40 from nonfatal myocardial infarctions, and 18 from nonfatal strokes. The baseline characteristics of the study population, based on the occurrence of a cardiovascular event during follow-up, are shown in Table 1 . The baseline concentration of SAH was significantly higher in those who had a cardiovascular event than in those who did not (25.4 compared with 23.0 nmol/L; P , 0.001). Higher plasma SAH concentrations were found in patients with diabetes and alcohol drinkers ( Table 2) . After adjustment for age and sex, there was a weak but significant correlation of SAH with tHcy (r = 0.07, P = 0.04), HDL (r = 20.07, P = 0.02), fasting blood glucose (r = 0.07, P = 0.01), and creatinine (r = 0.08, P = 0.007). No significant correlation was found between vitamin B-12 and folate with SAH. In contrast, the serum folate concentration, but not vitamin B-12, was significantly correlated with the plasma tHcy concentration (r = 20.160, P , 0.001).
Association of plasma SAH and tHcy with the risk of cardiovascular events
The Kaplan-Meier curves for event-free survival, based on quartiles of SAH concentrations, are shown in Figure 3 . The unadjusted rate of cardiovascular events increased in a stepwise fashion across increasing quartiles of baseline SAH concentration (P , 0.001 by log-rank test). The age-and sex-adjusted HRs of cardiovascular events across quartiles were 1.00, 2.25, 2.72, and 3.40 for SAH (P-trend = 0.007) and 1.00, 2.14, 2.47, and 2.44 for tHcy (P-trend = 0.04), respectively ( Table 3) . After further adjustment for traditional CVD risk factors (model 1 and model 2), plasma SAH, but not tHcy, was significantly associated with a risk of cardiovascular events. Because of the biological interplay between SAH and tHcy, and because both high SAH and tHcy concentrations were associated with an increased CVD risk, we studied the effect of adjusting the tHcy-cardiovascular event association for SAH and vice versa (model 3). The positive association between SAH and risk of cardiovascular events remained after adjustment for tHcy. In contrast, the association between tHcy and CVD risk was no longer significant after 1 P values for differences between the groups with and without cardiovascular events were calculated by using chisquare tests for categorical variables and t tests or Wilcoxon's rank-sum tests for continuous variables. CAD, coronary artery disease; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; tHcy, total homocysteine. 
Plasma SAH and CVD risk in various subgroups
In the multivariate analyses, the association between SAH and the risk of cardiovascular events did not change when participants were stratified by age, sex, level of obesity, smoking status, alcohol use, histories of hypertension and diabetes, serum folate and creatinine, and plasma SAM, tHcy, or cysteine. No significant interactions between SAH and any of these variables with CVD risk were identified (P-interaction . 0.05 for all) ( Table 4 ).
Combined effect of SAH and tHcy on the risk of cardiovascular events
A significantly higher CVD risk was observed in patients with a high concentrations of SAH but low concentrations of tHcy (HR: 2.15; 95% CI: 1.05, 4.42). This was also the case in patients with high concentrations of both SAH and tHcy (HR: 3.78; 95% CI: 1.93, 7.38) compared with patients with low concentrations of both SAH and tHcy after adjustment for all potential confounders ( Figure 4 ).
Sensitivity analyses
After the exclusion of participants without significant coronary stenosis, the association of SAH with cardiovascular events was similar in the remaining 861 patients with CAD compared with the entire sample. In the fully adjusted model, the participants with SAH in the highest quartile were at a 2.6-fold greater risk of cardiovascular events compared with those in the lowest quartile (HR: 2.67; 95% CI: 1.17, 6.12), and a 1-SD higher value in the natural log-transformed SAH was associated with a 2.4-fold greater risk of cardiovascular events (HR: 2.43; 95% CI: 1.45, 4.07).
DISCUSSION
In this prospective cohort of patients undergoing coronary angiography, we first showed a positive association between plasma SAH concentration and the risk of subsequent cardiovascular events. Further adjustment for other CVD risk factors affected the results only slightly. This positive association between SAH and CVD risk did not change by the stratified and sensitivity analyses.
SAH is the precursor of homocysteine in the methionine metabolic cycle, and severe elevated homocysteine concentrations may reversibly induce the increase in SAH (6) . The pathogenicity of intracellular SAH accumulation lies in its high binding affinity to the catalytic region of most methyltransferases, which enables it to act as a potent inhibitor (7). The elevated SAH concentrations would inhibit the methylation of many tissue components, including proteins, DNA, RNA, phospholipids, and other small molecules, which could result in changes in the phenotype of vascular cells and promotion of the development of atherosclerotic CAD (19, 20) . Another important methylation reaction that can promote atherogenesis, independently of changes in gene expression, is the methylation of 1 P values for differences, compared with the first category of each variable, were calculated by using general linear models that were adjusted for age, sex, BMI, hypertension, diabetes, smoking, alcohol use, history of CAD, physical activity, dietary energy, fiber, use of cholesterol-lowering agents, use of antidiabetic drugs, use of antihypertensive drugs, use of aspirin, and the variables for comparison. CAD, coronary artery disease; SAH, Sadenosylhomocysteine.
2 Estimated marginal means; 95% CIs in parentheses (all such values). L-arginine to asymmetric dimethylarginine and SAH as a byproduct. Asymmetric dimethylarginine can inhibit the activity of nitric oxide synthase and is associated with an increased risk of vascular disease in hyperhomocysteinemia (21) . As a result of the effect of SAH on the steady state equilibrium of methylation in vascular disease, high homocysteine concentrations are indirectly associated with reduced methylation (22, 23) .
These experimental findings were previously shown in crosssectional or case-control studies (8, 10, 24) . However, the relation between plasma SAH and CVD risk still needs to be further replicated in a prospective study. The current study is the first report that SAH is positively linked with the risk of cardiovascular events in a prospective setting. Our observations suggest that high concentrations of SAH are associated with an increased risk of cardiovascular events, independent of the effect of tHcy. Notably, the association of elevated tHcy with the risk of cardiovascular events depended on the concentrations of SAH, and high tHcy concentrations further increased the efficacy of SAH in predicting CVD risk. The synergistic effect of SAH and tHcy on the increased CVD risk is supported by a previous in vitro study by Lin et al (25) .
Several studies have noted the advantages of using SAH, rather than tHcy, as an indicator of CVD (26) . Some pathological conditions that lead to tHcy, such as renal dysfunction, may have a smaller effect on tHcy concentration than on SAH concentration (27, 28) . In end-stage renal failure, there are not only high concentrations of plasma tHcy but also much higher concentrations of SAH (24, 29) . Hence, elevated plasma SAH is a more sensitive and significant test of renal insufficiency than is tHcy. In the current study, although we found that SAH was significantly associated with serum creatinine, no significant difference in SAH concentrations was found between the patients with and without decreased renal function in the group with CVD events. Therefore, this might be ruled out in patients with CVD events and suggests that higher plasma SAH concentrations are associated with the risk of CVD events, independently of renal function. Moreover, the current study provides stronger evidence than previous small-sample retrospective studies and suggests that plasma SAH is a more sensitive indictor than is tHcy at identifying patients undergoing coronary angiography who are at the highest risk of cardiovascular events.
There are several important immediate products of the methionine metabolic cycle, including SAH, SAM, homocysteine, and cysteine. We found no significant association between SAM and CVD risk. Because homocysteine is converted to cysteine by transsulfuration, the latter was considered a risk factor for CVD in a case-control study (30) . However, plasma cysteine was not associated with CVD risk in the current study, which agrees with a previous prospective study (31) . Simultaneous adjustment for SAM and cysteine did not influence the association between SAH and CVD risk. In addition, the metabolic products of the methionine cycle are regulated by several other factors, such as vitamin B-12 and folic acids. In the current study, we found no significant correlation between SAH and vitamin B-12 and folate, which was consistent with a previous study (32) . Hence, B vitamin supplements might not directly affect SAH concentrations. However, it is unclear whether B vitamin supplements may indirectly affect SAH concentrations by modifying tHcy concentrations. On one hand, B vitamin supplements efficiently lower homocysteine concentrations and indirectly promote the hydrolysis of SAH. On the other hand, folic acid and vitamin B-12 supplements promote the remethylation of homocysteine to methionine, which in turn can be converted to SAM. In turn, this indirectly increases the methylation potential and SAH production. These opposing effects of B vitamin supplements may indirectly maintain the dynamic equilibrium of SAH concentrations. In the current study, the adjustment for the above CVD risk factors in the stratified analyses attenuated the association between SAH and CVD risk, but SAH remained a significant predictor of CVD risk in the multivariate model. The current study had some limitations. Measuring the concentrations of intermediates in the methionine metabolic pathway poses challenges because of the influence of dietary intake and analytic constraints on amino acid concentrations. Even though our study used fasting, acidified samples and quantitatively robust stable-isotope dilution mass spectrometry techniques, the mean SAH concentration in the Chinese population was slightly different from that in previous reports because of differences in race, disease conditions, and dietary patterns (8) (9) (10) . Furthermore, in the current study, the relation between SAH and CVD risk was analyzed only in diseased individuals. As such, the relation between SAH and CVD risk in the general healthy population needs further study. Last, proof of a cause-effect relation between increased SAH concentration and cardiovascular events cannot be established by this prospective cohort study. New treatment strategies are needed to determine whether a decrease in plasma SAH concentrations can eventually reduce CVD risks.
In conclusion, we found that an increased plasma SAH concentration was strongly associated with a higher risk of cardiovascular events among patients undergoing coronary angiography. This positive association suggests that SAH may be a better predictor of the risk of cardiovascular events than is tHcy.
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